ArticleCancer chemotherapy and pharmacology2019

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Filipa Lynce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.